Novotech Publishes Report on Research into Endometrial Cancer, a Leading Cause of Gynecology Malignancy Mortality
June 20 2024 - 10:53PM
Novotech, the global full-service clinical Contract Research
Organization (CRO) that partners with biotech companies to
accelerate the development of advanced and novel therapeutics at
every phase, has released a comprehensive research report -
Endometrial cancer - Global Clinical Trial Landscape.
The report provides insights and key data on the global
landscape of clinical trials for uterine cancer, primarily
endometrial cancer (EC), focusing on prevalence, funding landscape,
emerging trends, therapies, trial density, and patient recruitment
for trial planning and research.
Since 2018, over 1,200 EC clinical trials have been initiated
worldwide, with North America and Asia-Pacific contributing 39% and
33% of trials, respectively, followed by Europe at 22%.
EC ranks as the second most common, and fourth leading, cause of
death globally among gynecology malignancies. In 2022 alone, there
were nearly 420,370 new cases of EC globally, with approximately
97,720 deaths.
- Asia (167,430) accounts for nearly 40% of global cases of EC in
2022
- Europe (124,874)
- North America (73,977)
Within Asia:
- Mainland China reported the highest incidence with 77,722
cases
- The United States had the second-highest incidence globally
with 66,055 cases, accompanied by the highest ASR of 22.5 per
100,000 population
- In Europe, Russia reported the third-highest incidence with
29,852 cases
Currently, the standard of care for EC is surgery with either
partial or total hysterectomy and bilateral salpingo-oophorectomy
(TH/BSO). For recurrent EC patients, treatments vary based on
extent and prior success, including surgery, radiation, and
systemic therapy such as chemotherapy and hormonal
therapy.
The report notes that projections for EC show an increase in new
cases over the next 25 years, potentially surpassing 600,000 annual
new cases by 2044.
This demand for therapies has seen EC clinical trial activity
increase globally from 2014 to 2023, with the Asia-Pacific region
experiencing the highest increase with a Compound Annual Growth
Rate (CAGR) of 22.9%. ROW followed closely at 14.9%, and the North
American and European regions showed a steady growth rate at 9.7%
and 5.2% respectively.
Similarly, the funding landscape is strong with the United
States dominating in venture capital funding for EC research
between 2019 and 2023, followed by China, with investments
totalling $2129 million and $894 million, respectively. Public
funding initiatives in Australia and the United States focused on
expanding and improving the quality of care.
Further key clinical trial trend and treatment developments from
the report include:
- The United States led trial activity in North America, while
Mainland China led in the Asia-Pacific region, followed by
Australia and South Korea.
- The trial phase trends show North America and Asia-Pacific
conducting a higher volume of early and mid-phase trials (Phase 1
and 2), while Europe and the ROW concentrate on later-stage trials
(Phase 3).
- Asia-Pacific demonstrates the shortest median enrollment period
(15.1 months) and the highest median recruitment rate (1.1 subjects
per site per month), indicating efficient patient recruitment.
- There are approximately six drugs in preclinical stages, 15 in
Phase I trials, and 12 in combined Phase I/II studies.
- In Phase III trials, Programmed Cell Death 1 Ligand 1 Inhibitor
dominates the mechanism of action (MOA), followed by Programmed
Cell Death Protein 1 Antagonist and Poly [ADP Ribose] Polymerase 1
Inhibitor.
- Marketed drugs for EC mainly target DNA synthesis inhibitors,
progesterone receptor agonists, and tubulin inhibitors.
The Novotech research analyst team provides these expert reports
every month, completely free of charge. In addition to the
highlights above, the report provides an in-depth SWOT analysis, to
guide biotech firms on strategic decision-making, research
opportunities, and challenges. They tackle the potential and real
hurdles biotech firms face in specific therapeutic areas in the
hopes of positively impacting and informing clinical trial
decision-making, eventually improving success rates with new
treatments.
Download the report here
About Novotech Novotech-CRO.comFounded in 1997, Novotech is a
global full-service clinical Contract Research Organization (CRO)
focused on partnering with biotech companies to accelerate the
development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has
received numerous prestigious awards, including the CRO Leadership
Award 2023, the Asia Pacific Cell & Gene Therapy Clinical
Trials Excellence 2023, the Asia-Pacific Contract Research
Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including
laboratories, Phase I facilities, drug development consulting,
regulatory expertise, and has experience with over 5,000 clinical
projects, including Phase I to Phase IV clinical trials and
bioequivalence studies. With a presence in 34 office locations and
a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit
Novotech-CRO.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a2ce74ba-6793-437c-9766-0e04b71255ce
Media Contact
David James
mediacontact@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427